A randomised, placebo-controlled trial of glycopyrrolate for the treatment of noisy respiratory secretions at the end of life-A pilot study

INTERVENTION: Glycopyrrolate 0.4mg initial subcutaneous dose immediately followed by continuous subcutaneous infusion of 1.2mg/24hours ( 0.05mg/hr) for a total of 24 hours. CONDITION: Nosiy respiratory secretions at the end of life PRIMARY OUTCOME: Feasibilty measure by acrrual of 24 patients in 12 months SECONDARY OUTCOME: Interrater reliability of a Noisy respiratory secretions score (by two observers) and a noise meter. INCLUSION CRITERIA: Age > 18 years Life‐limiting illness (malignant or non‐malignant) Inpatient in a Palliative Care unit Able to provide informed consent prior to entering the terminal phase Willing to discuss end of life care.